PET-MR-PSA Prostate Cancer Recidive Study (PET-MR-PSA)
18F-Fluciclovine PET/MRI for Detection of Recurrent Prostate Cancer After Radical Treatment
Sponsor: Norwegian University of Science and Technology
Listed as NCT02562131, this observational or N/A phase trial focuses on Prostate Cancer Recurrent and remains ongoing. Sponsored by Norwegian University of Science and Technology, it has been updated 14 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Jul 2025 — Present [monthly]
Active Not Recruiting
-
Sep 2024 — Jul 2025 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Apr 2023 — Jul 2024 [monthly]
Active Not Recruiting
-
Apr 2022 — Apr 2023 [monthly]
Active Not Recruiting
▶ Show 9 earlier versions
-
Mar 2021 — Apr 2022 [monthly]
Active Not Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Mar 2019 — Mar 2020 [monthly]
Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Mar 2018 [monthly]
Recruiting NA
-
Jan 2017 — Oct 2017 [monthly]
Recruiting NA
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Norwegian University of Science and Technology
- St. Olavs Hospital
For direct contact, visit the study record on ClinicalTrials.gov .